Management

Richard Murray, Ph.D.

Chief Executive Officer and President

Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray joined Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research. There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He was the executive vice president and chief scientific officer at PDL BioPharma, and previously, he was co-founder and vice president of research at EOS Biotechnology, which was acquired in 2003 by Protein Design Labs. Prior to these executive level roles, he spent more than 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now Merck’s Biologics.

Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

Hugh Cole

Chief Business Officer and Head of Corporate Development

Hugh Cole brings to Jounce more than 25 years of industry experience in pharmaceutical and biotech management. Before joining the team, Mr. Cole most recently served as chief business officer for ARIAD Pharmaceuticals, where in under three years, he led nine business development transactions for the company and helped develop and implement ARIAD’s new corporate strategy. In addition to his former role at ARIAD, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, where he oversaw the company’s portfolio management and rare disease strategic planning processes. At Shire, Mr. Cole was also globally responsible for the development strategy and commercialization of the rare disease drug Firazyr®, and led several important transactions for the company. Prior to joining Shire, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals and served as senior director, business development and strategy at Millennium Pharmaceuticals. Earlier in his career, Mr. Cole worked as a management consultant for The Wilkerson Group, a leading consultancy focused on life science companies and, prior to that, as an investment analyst for Fred Alger Management, where he covered the biotechnology and pharmaceutical industries.

Mr. Cole earned his MBA in health care management and finance at the Wharton School and his A.B. in chemistry from Harvard University.

Kim Drapkin, CPA

Chief Financial Officer

Kim Drapkin brings to Jounce more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Drapkin has worked with Jounce since its inception, playing a key role in building Jounce’s financial infrastructure, and comes into this role with an already deep understanding of Jounce’s strategy and culture. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies, including Jounce, Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc. Previously, Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms. Drapkin spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP.

Stephen Farrand, Ph.D.

Chief Technical Officer

Stephen Farrand, Ph.D., is an industry veteran with more than 25 years of experience and unparalleled knowledge of clinical and commercial therapeutic protein process and manufacturing, most notably having played a leadership role for the development and first approval of Keytruda®, while serving as vice president, bioprocess development at Merck. In addition to his former role at Merck, Dr. Farrand is the former senior vice president, head of global manufacturing at NantKwest, where he was responsible for establishing process and development manufacturing capabilities for NantKwest’s cell therapy products. Prior to that, Dr. Farrand was vice president, global biologics & sterile product development at Schering-Plough Research Institute, before the company was acquired by Merck in 2009, and earlier, served as manufacturing director at Schering-Plough Manufacturing sites in Ireland & Singapore. Prior to Schering-Plough, Dr. Farrand held a variety of production and manufacturing positions at Delta Biotechnology, Ltd., Sigma Chemical Co. Ltd. and G D Searle & Co. Ltd.

Dr. Farrand earned his Ph.D. in microbial physiology from the University of Leicester, U.K., and his Bachelor of Science degree in microbiology from the University of Bath, U.K.

Elizabeth Trehu, M.D.

Chief Medical Officer

Elizabeth Trehu, M.D., brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and implementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier, held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Prior to that, she was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program.

Dr. Trehu received her A.B. in English Literature from Princeton University and her M.D. from New York University School of Medicine.

Anna L. Barry, Ph.D., J.D.

Senior Vice President, General Counsel & Secretary

Dr. Barry brings to Jounce more than 15 years of intellectual property, corporate and transactional legal experience in the biotechnology industry. Prior to joining Jounce Therapeutics, Dr. Barry was senior intellectual property counsel at Five Prime Therapeutics, where she managed all aspects of intellectual property related to the company’s therapeutic pipeline and platform technology. Prior to joining Five Prime Therapeutics, Dr. Barry served as senior patent counsel at Genentech, where she managed oncology and metabolism patent portfolios. Before Genentech, Dr. Barry was an attorney at Heller Ehrman LLP, where her practice focused on counseling life sciences and biotechnology companies.

Dr. Barry holds a J.D. from Vanderbilt University Law School, a Ph.D. in biophysical chemistry from Yale University and a B.S. in chemistry from Georgia Institute of Technology.

Ted Harding

Vice President, Human Resources

Ted Harding brings to Jounce almost twenty years of strategic and operational human resource experience including recruiting, compensation, acquisition and integration, organizational effectiveness, performance management, coaching, manager development, communication, new hire integration, and culture management. Mr. Harding brings with him the ability to develop and align human resources practices with business goals to add value from both a tactical and strategic perspective. Prior to joining Jounce, Mr. Harding served as president at Seed HR, and senior director at several pharmaceutical companies, including Alexion Pharmaceuticals, Enobia Pharma, TransMedics, Inc., and TransForm Pharmaceuticals, Inc. Mr. Harding also has experience in non-biotech organizations such as Boston-Power, Nortel Networks, Southern Company and Kraft Foods, making him a well-rounded, experienced human resources professional.

Mr. Harding received a master’s of industrial and labor relations from Cornell University, a bachelor’s degree in business and psychology from Hamline University, and an associate’s degree in chemical dependency counseling from Minneapolis Community and Technical College.

Allison Nance

Vice President, Regulatory Affairs & Quality Assurance

Allison Nance brings to Jounce over two decades of experience in global regulatory affairs with expertise in the development and licensing of drugs, biologics, medical devices and diagnostics. Mrs. Nance joined Jounce in May 2016 from Celgene, where she served as an executive director and member of the regulatory affairs leadership team with oversight of the early development portfolio for both the Hematology & Oncology and Inflammation & Immunology franchises. Her responsibilities included serving on company governance committees and joint development committees established for external biopharmaceutical collaborations. She was also the lead regulatory strategist for biomarkers and companion diagnostics supporting Hematology & Oncology programs and a member of joint steering committees for diagnostics partnerships. Mrs. Nance showed particular interest in promoting adoption of expedited regulatory programs for drugs and biologics intended to treat serious conditions and initiatives supporting personalized medicine. Prior to joining Celgene, Mrs. Nance served as the regulatory head of the Americas for GE Healthcare Medical Diagnostics and, prior to GE, held various positions in regulatory affairs at Roche and Baxter BioScience.

Mrs. Nance holds two B.S. degrees (general biology and ecology & evolutionary biology) from the University of Arizona and is pursuing a M.S. degree in biotechnology from Johns Hopkins University.

Board of Directors

Perry Karsen

Chairman

Perry A. Karsen, has served as a director on our board of directors since January 2016, and as the chairman of our board of directors since April 2016. Mr. Karsen is a venture partner with Third Rock Ventures, LLC, which he joined in 2016. Previously, Mr. Karsen was the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, or Celgene, from 2013 until his retirement in 2015. Mr. Karsen served as executive vice president and chief operations officer of Celgene from 2010 to 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Mr. Karsen was chief executive officer of Pearl Therapeutics Inc., from 2009 to 2010. Earlier in his career, Mr. Karsen held executive positions at Human Genome Sciences, Inc., Bristol-Myers Squibb Co., Genentech, Inc. and Abbott Laboratories. He is a member of the boards of directors of publicly traded life sciences companies Intellia Therapeutics, Inc. where he serves as chairman of the board, OncoMed Pharmaceuticals, Inc. and Voyager Therapeutics, Inc. Mr. Karsen received a Masters of Management from Northwestern University’s Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana- Champaign.

Luis A. Diaz, Jr., M.D.

Director

Luis A. Diaz, Jr., M.D. has served as a director on our board of directors since October 2017. Dr. Diaz is the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016, he was a faculty member and physician at the Johns Hopkins University School of Medicine. Dr. Diaz was a member of the renowned Ludwig Center for Cancer Genetics and Therapeutics, and was Director of the Swim Across America Laboratory. He also founded several entities that focus on genomic analyses of cancers including Inostics, PapGene and Personal Genome Diagnostics, Inc. As a clinical scientist, he has also harnessed the power of cancer mutations as potent antigens and championed the use of checkpoint inhibitors in the treatment of patients with tumors with high mutational burden. He and his team conceptualized and executed the landmark proof-of-concept study using PD-1 blockade in patients with MSI-H, which led to the historic first pan-tumor FDA approval for any solid tumors with this genetic lesion in May 2017. Dr. Diaz holds a B.S. in microbiology and an M.D. from the University of Michigan. He completed his internal medicine residency training at the Osler Medical Service and his medical oncology fellowship training at the Sidney Kimmel Cancer Center, both part of the Johns Hopkins University School of Medicine.

Barbara Duncan

Director

Barbara Duncan has served as a director on our board of directors since May 2016. Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc. from 2009 to 2016 and as treasurer from 2010 to 2016. From 2001 to 2009, Ms. Duncan served as chief financial officer and then chief executive officer at DOV Pharmaceutical, Inc. Previously, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from 1998 to 2001. She serves on the board of directors of Adaptimmune Therapeutics plc, Medgenics, Inc. and the boards of directors of other private companies. Ms. Duncan holds an M.B.A. from the Wharton School, University of Pennsylvania and a B.S. degree from Louisiana State University.

Duncan Higgons

Director

J. Duncan Higgons has served as a director on our board of directors since November 2015. Mr. Higgons recently served as chief operating officer of Agios Therapeutics, Inc., or Agios, from 2009 to 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.

Robert Kamen, Ph.D.

Director

Robert Kamen, Ph.D., has served as a member of our board of directors since June 2013. Dr. Kamen also served as our interim chief technology officer from 2013 to 2015. Dr. Kamen is an entrepreneur in residence at Third Rock Ventures, LLC, which he joined in 2010. From 2005 to 2010, Dr. Kamen served as the chairman of BioAssets Development Corporation. From 2002 to 2008, Dr. Kamen served as executive-in-residence at Oxford Bioscience Partners. From 2001 to 2002 he served as president of Abbot Laboratories’ Abbot Bioresearch Center and as a member of the Abbot Pharma Executive Management Committee. From 1991 to 2001, he served as the president of BASF Bioresearch Corporation. Dr. Kamen serves on the boards of directors for numerous companies, including BioAssets Development Corporation, Inc., EpimAb Biotherapeutics, Inc., Harbour Antibodies BV, Lycera Corporation, Opsonic Therapeutics Inc. and Neon Therapeutics, Inc. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College.

Richard Murray, Ph.D.

Chief Executive Officer and President

Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray joined Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research. There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He was the executive vice president and chief scientific officer at PDL BioPharma, and previously, he was co-founder and vice president of research at EOS Biotechnology, which was acquired in 2003 by Protein Design Labs. Prior to these executive level roles, he spent more than 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now Merck’s Biologics.

Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

Cary Pfeffer, M.D.

Director

Cary G. Pfeffer, M.D., has served as a director on our board of directors since February 2013. Previously, Dr. Pfeffer served as the chairman of our board from 2014 to 2016, and as our interim chief executive officer from 2013 to 2014. Dr. Pfeffer is a partner at Third Rock Ventures, LLC, which he joined in 2007.

Dr. Pfeffer was the interim chief executive officer of Neon Therapeutics, Inc. from 2015 to 2016. Dr. Pfeffer served at Biogen Inc. from 1992 to 2002 in a variety of domestic and international executive management roles. Dr. Pfeffer serves on the boards of directors for Ablexis, LLC, Edimer Pharmaceuticals, Inc., and Neon Therapeutics, Inc. where he serves as chairman of the board. Dr. Pfeffer received an M.B.A. from the Wharton School, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University.

Robert Tepper, M.D.

Director

Robert Tepper, M.D., has served as a member of our board of directors since February 2013. Previously, Dr. Tepper served as our interim chief scientific officer from 2013 to 2015. Since 2007, Dr. Tepper has served as a partner at Third Rock Ventures, LLC, which he co-founded in 2007. Since 2014, Dr. Tepper is currently the interim chief scientific officer of Neon Therapeutics, Inc. Prior to joining Third Rock Ventures, LLC, Dr. Tepper held multiple positions at Millennium Pharmaceuticals, Inc., including service as president of research and development from 2002 to 2007, executive vice president of discovery from 2001 to 2002 and chief scientific officer from 1999 to 2002. Dr. Tepper serves on the boards of directors for numerous companies, including Alcresta, Inc., Allena Pharmaceuticals, Inc., Constellation Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., and Neon Therapeutics, Inc. Previously, Dr. Tepper served on the boards of Bluebird Bio, Inc. and Alnara Pharmaceuticals, Inc. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University.

Company Founders

James P. Allison, Ph.D.

Chair, The University of Texas MD Anderson Cancer Center Department of Immunology

James Allison is a co-founder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the T-cell antigen receptor protein. His research led to the clinical development of ipilimumab (Yervoy™), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial Sloan-Kettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial Sloan-Kettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received worldwide recognition for his contributions, including, the 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation, the Lasker Clinical Medical Research Award, the Canada Gairdner International Award, the Szent-Györgyi Prize for Progress in Cancer Research and the Breakthrough Prize in Life Sciences for Innovative Cancer Immunology Research.

Dr. Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.

Thomas F. Gajewski, M.D., Ph.D.

Professor, Departments of Pathology and Medicine, University of Chicago

Thomas Gajewski is a scientific co-founder of Jounce Therapeutics and currently serves as professor, departments of pathology and medicine, section of hematology/oncology at the University of Chicago. There, he is leader of the immunology and cancer program of the Cancer Center, and also directs the Melanoma Oncology Clinic. Dr. Gajewski is the immediate past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research and JITC. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. Dr. Gajewski also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials. He has served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

Drew Pardoll, M.D., Ph.D.

Abeloff Professor of Oncology, Director, Cancer Immunology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Dr. Pardoll is a scientific co-founder of Jounce Therapeutics and an Abeloff Professor of oncology, medicine, pathology and molecular biology and genetics at the Johns Hopkins University School of Medicine. He is also director of cancer immunology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Pardoll has published more than 250 papers and more than 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma – delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. Dr. Pardoll’s basic immunology discoveries include the identification of γδ-T cells, NKT cells and IKDC. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Dr. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. His more than 250 articles cover cancer vaccines, gene therapies, cancer prevention technologies, recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases.

Robert Schreiber, Ph.D.

Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, Director of the Center for Human Immunology and Immunotherapy programs, Washington University School of Medicine

A leader in the study of tumor immunology, Bob Schreiber is a senior scientific adviser to Jounce Therapeutics and currently serves as the alumni endowed professor of pathology and immunology, professor of molecular microbiology, co-leader of the tumor immunology program for the Siteman Comprehensive Cancer Center, and director of the Center for Human Immunology and Immunotherapy Programs (CHiiPs) at Washington University School of Medicine in St. Louis. He is an associate director of the Cancer Research Institute, a member of the US National Academy of Sciences and the American Academy of Arts and Sciences, a fellow of the American Association of Science, a past member of the board of scientific advisers for the National Cancer Institute, and a past president of the Society for Leukocyte Biology. Dr. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work formed the basis for the concept of cancer immunoediting that helped reveal that the immune system is not only capable of destroying cancers, but can sometimes also either hold cancers in a dormant state or sculpt their immunogenicity thereby enhancing their malignancy. His lab is highly regarded for its research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. Dr. Schreiber’s group unequivocally demonstrated that the immune system provides an extrinsic tumor suppressor function (cancer immunosurveillance) capable of eliminating spontaneous- and carcinogen-induced primary tumors. He has authored more than 300 peer reviewed and invited publications and has received several honors, including the Milstein Award for Outstanding Achievements in Research on Interferon and Cytokines from the International Society of Interferon and Cytokine Research, the Bonazinga Award for Excellence in Leukocyte Biology Research from the Society for Leukocyte Biology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute, the Charles Rodolphe Brupbacher Award for Cancer Research from the Brupbacher Cancer Foundation in Switzerland and the AACR-CRI Lloyd J. Old Award in Cancer Immunology awarded jointly by the American Association for Cancer Research and Cancer Research Institute.

Padmanee Sharma, M.D., Ph.D.

Leading cancer immunotherapy translational scientist, Dr. Sharma is a co-founder of Jounce Therapeutics and currently serves as scientific director and professor in the departments of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting anti-tumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including a Department of Defense (DOD) Idea Development Award (2010), a Cancer Prevention Research Institute of Texas (CPRIT) Individual Investigator Award (2011), a National Institute of Health (NIH/NCI) R01 Award (2012) and an AACR-CRI-SU2C Immunotherapy dream team grant (2013).

Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She also holds a B.A. in biology and an M.A. in biotechnology from Boston University.

Louis M. Weiner, M.D.

Internationally recognized medical oncologist Louis Weiner is a scientific co-founder of Jounce Therapeutics and an accomplished researcher developing novel immunotherapy treatments in his laboratory. As director of the Lombardi Comprehensive Cancer Center, professor and chair of the department of oncology, Francis L. and Charlotte G. Gragnani Chair and associate vice president of Georgetown University Medical Center, Dr. Weiner is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. Dr. Weiner is recognized for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies, and the use of functional genomics tools to improve the anti-tumor consequences of antibody-targeted therapy. Prior to Lombardi, Dr. Weiner served as chairman of the medical oncology department and vice president for Translational Research at Fox Chase Cancer Center in Philadelphia, where he held an endowed chair in medical science and was the driving force behind developing an immunotherapy laboratory and clinical program, as well as establishing the Center’s medical oncology fellowship program. Dr. Weiner has published more than 200 scientific papers and lectures extensively on targeted therapies for cancer. He served as Fox Chase Cancer Center’s principal investigator for the Eastern Cooperative Oncology Group (ECOG) from 1994 until 2002, a major national study group working to improve cancer treatment through clinical trials. Dr. Weiner is the founding and past chair of the Cancer Immunology Working Group of the American Association of Cancer Research, as well as past course co-director for the annual AACR/ASCO Clinical Methods Workshop. He serves as chair of the NCI Board of Scientific Counselors, and on the NExT Oversight Committee. Dr. Weiner also serves on several journal editorial boards, including Cancer Research and Clinical Cancer Research.

Dr. Weiner received his MD from Mount Sinai School of Medicine at New York University and his BA in biology from the University of Pennsylvania.